WO2007038453A2 - Administration d'un agent pour l'amelioration de l'inflammation - Google Patents

Administration d'un agent pour l'amelioration de l'inflammation Download PDF

Info

Publication number
WO2007038453A2
WO2007038453A2 PCT/US2006/037332 US2006037332W WO2007038453A2 WO 2007038453 A2 WO2007038453 A2 WO 2007038453A2 US 2006037332 W US2006037332 W US 2006037332W WO 2007038453 A2 WO2007038453 A2 WO 2007038453A2
Authority
WO
WIPO (PCT)
Prior art keywords
agent
vegf
ocular
inflammatory
formulation
Prior art date
Application number
PCT/US2006/037332
Other languages
English (en)
Other versions
WO2007038453A3 (fr
Inventor
Gholam Ali Peyman
Original Assignee
Advanced Ocular Systems Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/234,970 external-priority patent/US20070071754A1/en
Priority claimed from US11/348,465 external-priority patent/US20070072933A1/en
Priority claimed from US11/348,017 external-priority patent/US20070071756A1/en
Application filed by Advanced Ocular Systems Limited filed Critical Advanced Ocular Systems Limited
Publication of WO2007038453A2 publication Critical patent/WO2007038453A2/fr
Publication of WO2007038453A3 publication Critical patent/WO2007038453A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention a trait à un procédé d'administration d'un agent anti-facteur croissance endothéliale vasculaire pour l'amélioration de l'inflammation à un site dans l'organisme qui peut être l'oeil, une articulation, le cerveau ou autres ou pour la réduction de la néovascularisation cornéenne. Dans un mode de réalisation, un ou plusieurs autres agents, tels que des agents anti-inflammatoires non stéroïdes, stéroïdes et autres peuvent être inclus avec l'agent anti-facteur croissance endothéliale vasculaire. L'agent anti-facteur croissance endothéliale vasculaire peut être le bevacizumab, le ranibizumab, le sunitinib maléate, le pegaptanib, et autres.
PCT/US2006/037332 2005-09-26 2006-09-26 Administration d'un agent pour l'amelioration de l'inflammation WO2007038453A2 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US11/234,970 2005-09-26
US11/234,970 US20070071754A1 (en) 2005-09-26 2005-09-26 Method to ameliorate inflammation
US11/348,017 2006-02-06
US11/348,465 US20070072933A1 (en) 2005-09-26 2006-02-06 Delivery of an ocular agent
US11/348,017 US20070071756A1 (en) 2005-09-26 2006-02-06 Delivery of an agent to ameliorate inflammation
US11/348,465 2006-02-06

Publications (2)

Publication Number Publication Date
WO2007038453A2 true WO2007038453A2 (fr) 2007-04-05
WO2007038453A3 WO2007038453A3 (fr) 2007-11-29

Family

ID=37806769

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/037332 WO2007038453A2 (fr) 2005-09-26 2006-09-26 Administration d'un agent pour l'amelioration de l'inflammation

Country Status (1)

Country Link
WO (1) WO2007038453A2 (fr)

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009021150A2 (fr) * 2007-08-08 2009-02-12 California Pacific Medical Center Le récepteur du facteur de croissance dérivés des plaquettes tolère l'infectiosité du cytomégalovirus
DE102007038730A1 (de) * 2007-08-16 2009-02-19 Carl Zeiss Meditec Ag Nachweis des menschlichen Vascular Endothelial Growth Factor
WO2009105534A3 (fr) * 2008-02-21 2009-11-05 Ista Pharmaceuticals Ains ophtalmiques utilisés comme adjuvants
WO2010069073A1 (fr) * 2008-12-16 2010-06-24 Qlt Inc. Combinaison d'une thérapie photodynamique et d'agents anti-vegf dans le traitement d'une néovascularisation choroïdienne indésirable
WO2010119306A1 (fr) * 2009-04-15 2010-10-21 Fondazione Irccs Istituto Nazionale Dei Tumori Utilisation d'inhibiteurs de multiples kinases dans le traitement d'une hyperperméabilité vasculaire
WO2013188283A1 (fr) * 2012-06-12 2013-12-19 Bayer Healthcare Llc Composition pharmaceutique ophtalmique topique contenant du sunitinib
US8747852B1 (en) 2012-12-28 2014-06-10 Randal Tanh Hoang Pham Methods of treating pterygium
US20150045296A1 (en) * 2012-03-29 2015-02-12 Xavier University Of Louisiana Method for treating diabetic retinopathy
US9066779B2 (en) 2009-01-29 2015-06-30 Forsight Vision4, Inc. Implantable therapeutic device
EP2242464B2 (fr) † 2007-12-20 2017-03-01 University Of Southern California Appareil pour distribuer des agents thérapeutiques
US9851351B2 (en) 2009-01-29 2017-12-26 Forsight Vision4, Inc. Posterior segment drug delivery
US9861521B2 (en) 2010-08-05 2018-01-09 Forsight Vision4, Inc. Injector apparatus and method for drug delivery
US9883968B2 (en) 2011-09-16 2018-02-06 Forsight Vision4, Inc. Fluid exchange apparatus and methods
US9895369B2 (en) 2014-08-08 2018-02-20 Forsight Vision4, Inc Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
US9968603B2 (en) 2013-03-14 2018-05-15 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
US9980901B2 (en) 2015-06-06 2018-05-29 Cloudbreak Therapeutics, Llc Compositions and methods for treating pterygium
US10010448B2 (en) 2012-02-03 2018-07-03 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
US10154994B2 (en) 2015-06-22 2018-12-18 Allgenesis Biotherapeutics, Inc. Ophthalmic formulations of tyrosine kinase inhibitors, methods of use thereof, and preparation methods thereof
RU2676303C2 (ru) * 2013-07-11 2018-12-27 Новартис Аг Использование антагониста vegf для лечения ретролентальной фиброплазии
US10166142B2 (en) 2010-01-29 2019-01-01 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
US10258503B2 (en) 2014-07-15 2019-04-16 Forsight Vision4, Inc. Ocular implant delivery device and method
US10398592B2 (en) 2011-06-28 2019-09-03 Forsight Vision4, Inc. Diagnostic methods and apparatus
US10398593B2 (en) 2013-03-28 2019-09-03 Forsight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
US10500091B2 (en) 2014-11-10 2019-12-10 Forsight Vision4, Inc. Expandable drug delivery devices and methods of use
US10617557B2 (en) 2010-08-05 2020-04-14 Forsight Vision4, Inc. Combined drug delivery methods and apparatus
US10688092B2 (en) 2016-06-02 2020-06-23 Cloudbreak Therapeutics, Llc Compositions and methods of using nintedanib for improving glaucoma surgery success
US10874548B2 (en) 2010-11-19 2020-12-29 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
US11419759B2 (en) 2017-11-21 2022-08-23 Forsight Vision4, Inc. Fluid exchange apparatus for expandable port delivery system and methods of use
US11432959B2 (en) 2015-11-20 2022-09-06 Forsight Vision4, Inc. Porous structures for extended release drug delivery devices
US11617680B2 (en) 2016-04-05 2023-04-04 Forsight Vision4, Inc. Implantable ocular drug delivery devices

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2600812B1 (fr) 2010-08-05 2021-09-22 ForSight Vision4, Inc. Dispositif pour traiter un oeil

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050058688A1 (en) * 2003-02-22 2005-03-17 Lars Boerger Device for the treatment and prevention of disease, and methods related thereto
WO2005074942A1 (fr) * 2004-02-04 2005-08-18 Retmed Pty Ltd Composition steroide a liberation lente
US20050192429A1 (en) * 2001-04-13 2005-09-01 Rosen Craig A. Vascular endothelial growth factor 2
WO2005084188A2 (fr) * 2004-02-25 2005-09-15 Massachusetts Eye & Ear Infirmary Marqueurs d'inflammation systemique et degenerescence maculaire liee a l'age (amd)
WO2005110362A1 (fr) * 2004-04-30 2005-11-24 Allergan, Inc. Implants oculaires biodegradables a caracteristiques de liberation a longue echeance
US20060182783A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
WO2006088650A2 (fr) * 2005-02-02 2006-08-24 Regeneron Pharmaceuticals, Inc. Methode de traitement de lesion oculaire par l'administration locale d'un inhibiteur de vegf
WO2007011873A2 (fr) * 2005-07-15 2007-01-25 Genentech, Inc. Procede permettant de traiter des maladies neovasculaires intraoculaires
WO2007047626A1 (fr) * 2005-10-14 2007-04-26 Alcon, Inc. Traitement de combinaison comprenant de l'acetate d'anecortave et du bevacizumab ou du ranibizumab pour une angiogenese oculaire pathologique

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1180024A (ja) * 1997-09-12 1999-03-23 Toagosei Co Ltd 角膜血管新生阻害剤

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050192429A1 (en) * 2001-04-13 2005-09-01 Rosen Craig A. Vascular endothelial growth factor 2
US20050058688A1 (en) * 2003-02-22 2005-03-17 Lars Boerger Device for the treatment and prevention of disease, and methods related thereto
WO2005074942A1 (fr) * 2004-02-04 2005-08-18 Retmed Pty Ltd Composition steroide a liberation lente
WO2005084188A2 (fr) * 2004-02-25 2005-09-15 Massachusetts Eye & Ear Infirmary Marqueurs d'inflammation systemique et degenerescence maculaire liee a l'age (amd)
WO2005110362A1 (fr) * 2004-04-30 2005-11-24 Allergan, Inc. Implants oculaires biodegradables a caracteristiques de liberation a longue echeance
US20060182783A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
WO2006088650A2 (fr) * 2005-02-02 2006-08-24 Regeneron Pharmaceuticals, Inc. Methode de traitement de lesion oculaire par l'administration locale d'un inhibiteur de vegf
WO2007011873A2 (fr) * 2005-07-15 2007-01-25 Genentech, Inc. Procede permettant de traiter des maladies neovasculaires intraoculaires
WO2007047626A1 (fr) * 2005-10-14 2007-04-26 Alcon, Inc. Traitement de combinaison comprenant de l'acetate d'anecortave et du bevacizumab ou du ranibizumab pour une angiogenese oculaire pathologique

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
AMANO SHIRO ET AL: "Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization" IOVS, vol. 39, no. 1, January 1998 (1998-01), pages 18-22, XP008079338 *
BEER P M ET AL: "VITREOUS LEVELS OF UNBOUND BEVACIZUMAB AND UNBOUND VASCULAR ENDOTHELIAL GROWTH FACTOR IN TWO PATIENTS" RETINA, PHILADELPHIA, PA, US, vol. 26, no. 8, 2006, pages 871-876, XP008079356 ISSN: 0275-004X *
DATABASE WPI 25 March 1999 (1999-03-25), Derwent Publications Ltd., London, GB; Class 991,page 9, AN 1999-229406 XP002437620 KAWAKAMI Y. ET AL.: "Corneal neovascularisation inhibitors" & WO 99/13909 A (TOA GOSEI CHEM IND LTD; TOA GOSEI KK) 25 March 1999 (1999-03-25) *
KANTOFF PHILIP: "RECENT PROGRESS IN MANAGEMENT OF ADVANCED PROSTATE CANCER" ONCOLOGY, PRR, HUNTINGTON, NY, US, vol. 19, no. 5, April 2005 (2005-04), pages 631-636, XP008079352 ISSN: 0890-9091 *
MICHELS STEPHAN ET AL: "Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study." OPHTHALMOLOGY JUN 2005, vol. 112, no. 6, June 2005 (2005-06), pages 1035-1047, XP005825968 ISSN: 1549-4713 *
ROSENFELD PHILIP J ET AL: "OPTICAL COHERENCE TOMOGRAPHY FINDINGS AFTER AN INTRAVITREAL INJECTION OF BEVACIZUMAB (AVASTIN) FOR MACULAR EDEMA FROM CENTRAL RETINAL VEIN OCCLUSION" OPHTHALMIC SURGERY, LASERS AND IMAGING, SLACK, INC., THOROFARE, NJ, US, vol. 36, no. 4, July 2005 (2005-07), - August 2005 (2005-08) pages 336-339, XP008079763 ISSN: 1542-8877 *
ROSENFELD PHILIP J ET AL: "OPTICAL COHERENCE TOMOGRAPHY FINDINGS AFTER AN INTRAVITREAL INJECTION OF BEVACIZUMAB (AVASTIN) FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION" OPHTHALMIC SURGERY, LASERS AND IMAGING, SLACK, INC., THOROFARE, NJ, US, vol. 36, no. 4, 22 June 2005 (2005-06-22), pages 331-335, XP008079762 ISSN: 1542-8877 *
SUGITA S: "Intravitreal anti-inflammatory treatment for uveitis" BRITISH JOURNAL OF OPHTHALMOLOGY 2007 UNITED KINGDOM, vol. 91, no. 2, 2007, pages 135-136, XP008079353 ISSN: 0007-1161 *

Cited By (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8435510B2 (en) 2007-08-08 2013-05-07 Sutter West Bay Hospitals Platelet derived growth factor receptor supports cytomegalovirus infectivity
WO2009021150A3 (fr) * 2007-08-08 2009-03-26 California Pacific Med Center Le récepteur du facteur de croissance dérivés des plaquettes tolère l'infectiosité du cytomégalovirus
US9340788B2 (en) 2007-08-08 2016-05-17 Sutter West Bay Hospitals Platelet derived growth factor receptor supports cytomegalovirus infectivity
WO2009021150A2 (fr) * 2007-08-08 2009-02-12 California Pacific Medical Center Le récepteur du facteur de croissance dérivés des plaquettes tolère l'infectiosité du cytomégalovirus
DE102007038730A1 (de) * 2007-08-16 2009-02-19 Carl Zeiss Meditec Ag Nachweis des menschlichen Vascular Endothelial Growth Factor
EP2242464B2 (fr) † 2007-12-20 2017-03-01 University Of Southern California Appareil pour distribuer des agents thérapeutiques
JP2011513229A (ja) * 2008-02-21 2011-04-28 イスタ・ファーマスーティカルズ・インコーポレイテッド 補助剤としての眼科用ｎｓａｉｄ
WO2009105534A3 (fr) * 2008-02-21 2009-11-05 Ista Pharmaceuticals Ains ophtalmiques utilisés comme adjuvants
JP2012512184A (ja) * 2008-12-16 2012-05-31 キュー エル ティー インク． 眼の状態に関する光線力学的療法
WO2010069073A1 (fr) * 2008-12-16 2010-06-24 Qlt Inc. Combinaison d'une thérapie photodynamique et d'agents anti-vegf dans le traitement d'une néovascularisation choroïdienne indésirable
AU2009327266B2 (en) * 2008-12-16 2015-10-29 Valeant Pharmaceuticals International, Inc. Combination of photodynamic therapy and anti-VEGF agents in the treatment of unwanted choroidal neovasculature
US9226917B2 (en) 2008-12-16 2016-01-05 Valeant Pharmaceuticals International, Inc. Photodynamic therapy for conditions of the eye
US9851351B2 (en) 2009-01-29 2017-12-26 Forsight Vision4, Inc. Posterior segment drug delivery
US10656152B2 (en) 2009-01-29 2020-05-19 Forsight Vision4, Inc. Posterior segment drug delivery
US11642310B2 (en) 2009-01-29 2023-05-09 Forsight Vision4, Inc. Posterior segment drug delivery
US9066779B2 (en) 2009-01-29 2015-06-30 Forsight Vision4, Inc. Implantable therapeutic device
US10813788B2 (en) 2009-01-29 2020-10-27 Forsight Vision4, Inc. Implantable therapeutic device
WO2010119306A1 (fr) * 2009-04-15 2010-10-21 Fondazione Irccs Istituto Nazionale Dei Tumori Utilisation d'inhibiteurs de multiples kinases dans le traitement d'une hyperperméabilité vasculaire
US10166142B2 (en) 2010-01-29 2019-01-01 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
US11679027B2 (en) 2010-08-05 2023-06-20 Forsight Vision4, Inc. Combined drug delivery methods and apparatus
US11786396B2 (en) 2010-08-05 2023-10-17 Forsight Vision4, Inc. Injector apparatus and method for drug delivery
US9861521B2 (en) 2010-08-05 2018-01-09 Forsight Vision4, Inc. Injector apparatus and method for drug delivery
US10617557B2 (en) 2010-08-05 2020-04-14 Forsight Vision4, Inc. Combined drug delivery methods and apparatus
US10265215B2 (en) 2010-08-05 2019-04-23 Forsight Vision4, Inc. Injector apparatus and method for drug delivery
US10874548B2 (en) 2010-11-19 2020-12-29 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
US11065151B2 (en) 2010-11-19 2021-07-20 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
US11813196B2 (en) 2011-06-28 2023-11-14 Forsight Vision4, Inc. Diagnostic methods and apparatus
US10398592B2 (en) 2011-06-28 2019-09-03 Forsight Vision4, Inc. Diagnostic methods and apparatus
US10653554B2 (en) 2011-09-16 2020-05-19 Forsight Vision4, Inc. Fluid exchange apparatus and methods
US9883968B2 (en) 2011-09-16 2018-02-06 Forsight Vision4, Inc. Fluid exchange apparatus and methods
US10010448B2 (en) 2012-02-03 2018-07-03 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
US10603209B2 (en) 2012-02-03 2020-03-31 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
US20150045296A1 (en) * 2012-03-29 2015-02-12 Xavier University Of Louisiana Method for treating diabetic retinopathy
US9636299B2 (en) * 2012-03-29 2017-05-02 Xavier University Of Louisiana Method for treating diabetic retinopathy
WO2013188283A1 (fr) * 2012-06-12 2013-12-19 Bayer Healthcare Llc Composition pharmaceutique ophtalmique topique contenant du sunitinib
US8747852B1 (en) 2012-12-28 2014-06-10 Randal Tanh Hoang Pham Methods of treating pterygium
US9161978B2 (en) 2012-12-28 2015-10-20 Randal Tanh Hoang Pham Methods of treatment of pterygium using an anti-VEGF agent
US10556008B2 (en) 2012-12-28 2020-02-11 Randal Tanh Hoang Pham Methods of treatment of keloid using an anti-VEGF agent
WO2014105978A1 (fr) * 2012-12-28 2014-07-03 Pham Randal Tanh Hoang Procédés de traitement utilisant le bévacizumab
US9968603B2 (en) 2013-03-14 2018-05-15 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
US10398593B2 (en) 2013-03-28 2019-09-03 Forsight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
US11510810B2 (en) 2013-03-28 2022-11-29 Forsight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
RU2676303C2 (ru) * 2013-07-11 2018-12-27 Новартис Аг Использование антагониста vegf для лечения ретролентальной фиброплазии
US10258503B2 (en) 2014-07-15 2019-04-16 Forsight Vision4, Inc. Ocular implant delivery device and method
US11337853B2 (en) 2014-07-15 2022-05-24 Forsight Vision4, Inc. Ocular implant delivery device and method
US10765677B2 (en) 2014-08-08 2020-09-08 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
US10363255B2 (en) 2014-08-08 2019-07-30 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
US9895369B2 (en) 2014-08-08 2018-02-20 Forsight Vision4, Inc Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
US11110001B2 (en) 2014-11-10 2021-09-07 Forsight Vision4, Inc. Expandable drug delivery devices and methods of use
US10500091B2 (en) 2014-11-10 2019-12-10 Forsight Vision4, Inc. Expandable drug delivery devices and methods of use
US10149820B2 (en) 2015-06-06 2018-12-11 Cloudbreak Therapeutics, Llc Compositions and methods for treating pterygium
US10149819B2 (en) 2015-06-06 2018-12-11 Cloudbreak Therapeutics, Llc Compositions and methods for treating hyperemia
US9987223B2 (en) 2015-06-06 2018-06-05 Cloudbreak Therapeutics, Llc Compositions and methods for treating pterygium
US10980741B2 (en) 2015-06-06 2021-04-20 Cloudbreak Therapeutics, Llc Compositions and methods for treating pterygium recurrence
US9980901B2 (en) 2015-06-06 2018-05-29 Cloudbreak Therapeutics, Llc Compositions and methods for treating pterygium
CN108135737A (zh) * 2015-06-06 2018-06-08 克劳德布雷克医疗有限责任公司 用于治疗翼状胬肉的组合物和方法
US11369600B2 (en) 2015-06-22 2022-06-28 Allgenesis Biotherapeutics Inc. Ophthalmic formulations of tyrosine kinase inhibitors, methods of use thereof, and preparation methods thereof
US10154994B2 (en) 2015-06-22 2018-12-18 Allgenesis Biotherapeutics, Inc. Ophthalmic formulations of tyrosine kinase inhibitors, methods of use thereof, and preparation methods thereof
US11432959B2 (en) 2015-11-20 2022-09-06 Forsight Vision4, Inc. Porous structures for extended release drug delivery devices
US11617680B2 (en) 2016-04-05 2023-04-04 Forsight Vision4, Inc. Implantable ocular drug delivery devices
US10688092B2 (en) 2016-06-02 2020-06-23 Cloudbreak Therapeutics, Llc Compositions and methods of using nintedanib for improving glaucoma surgery success
US11246864B2 (en) 2016-06-02 2022-02-15 Ads Therapeutics Llc Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization
US11911379B2 (en) 2016-06-02 2024-02-27 Ads Therapeutics Llc Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization
US11419759B2 (en) 2017-11-21 2022-08-23 Forsight Vision4, Inc. Fluid exchange apparatus for expandable port delivery system and methods of use

Also Published As

Publication number Publication date
WO2007038453A3 (fr) 2007-11-29

Similar Documents

Publication Publication Date Title
WO2007038453A2 (fr) Administration d'un agent pour l'amelioration de l'inflammation
US20070072933A1 (en) Delivery of an ocular agent
US20080003219A1 (en) Delivery of an ocular agent
US20070071756A1 (en) Delivery of an agent to ameliorate inflammation
US20080167600A1 (en) Device for delivery of an agent to the eye and other sites
ES2326550T3 (es) Uso de un macrolido para restablecer la sensacion corneal.
Seal et al. Intracameral sustained-release bimatoprost implant delivers bimatoprost to target tissues with reduced drug exposure to off-target tissues
EP1904056B1 (fr) Utilisation d'un macrolide pour restaurer la sensation cornéenne
Sivaprasad et al. Intravitreal steroids in the management of macular oedema
US20140011809A1 (en) Drug delivery to the anterior and posterior segments of the eye using eye drops
WO2010125416A1 (fr) Administration de médicaments dans le segment antérieur et le segment postérieur de l'oeil
KR20080059280A (ko) 녹내장의 원발성 및 ２차 형태의 치료 방법
JP2007523911A (ja) 眼病変治療用テトラサイクリン誘導体
JP2007512352A (ja) 黄斑変性およびその他の眼科疾患の改善
JP2011530496A (ja) 眼新生血管形成症状の治療のためのソラフェニブを含む眼科用医薬組成物
US20040127472A1 (en) Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration
US20050261243A1 (en) Antiprostaglandins for the treatment of ocular pathologies
KR20010113918A (ko) 후안부 안과 질환을 치료하고 예방하기 위한 방법 및 조성물
Peyman et al. Combination therapies in ophthalmology: implications for intravitreal delivery
Cholkar et al. Compositions, formulation, pharmacology, pharmacokinetics, and toxicity of topical, periocular, and intravitreal ophthalmic drugs
Papangkorn et al. A novel ocular drug delivery system of dexamethasone sodium phosphate for noninfectious uveitis treatment
US20070043006A1 (en) Formulations of non-steroidal anti-inflammatory agents to treat pathologic ocular angiogenesis
Pérez-Sarriegui et al. Phaco-non-penetrating deep sclerectomy in ocular hypertension secondary to dexamethasone intravitreal implant
Agrawal et al. Applications, model study and commercial utilization (patents) of ophthalmic route as drug delivery site
Aswin Outcome of glaucoma surgery in patients on prostaglandin analogues

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06815379

Country of ref document: EP

Kind code of ref document: A2